The study, published in the journal CVIR Oncology, explored whether proton magnetic resonance spectroscopy, often abbreviated as 1H-MRS, could identify the key components of a TACE procedure in a laboratory setting. Unlike conventional MRI, which produces anatomical images based on water and fat signals, magnetic resonance spectroscopy reads the chemical composition of tissue. Every molecule containing hydrogen protons resonates at a slightly different frequency, measured in parts per million on a chemical shift scale, and the resulting spectrum acts like a molecular barcode. Clinicians already use this method to measure metabolites in the brain, where markers such as N-acetylaspartate and lactate help diagnose tumors, strokes, and metabolic disease. The Marburg team asked a bolder question: could the same technique pick out a chemotherapy drug and its delivery vehicles amid the dense chemical noise of liver tissue?

To find out, the researchers used a preclinical 7 Tesla MRI scanner, roughly double the field strength of most clinical machines, and performed two-dimensional single-voxel spectroscopy using a STEAM sequence. Each measurement sampled a tiny cube of tissue just five millimeters on each side, with an echo time of 27 milliseconds, a repetition time of 2500 milliseconds, and 128 phase-encoding steps acquired over about five and a half minutes. They tested three substances central to TACE: doxorubicin, the cytostatic drug; Embozene TANDEM drug-eluting beads, microscopic polymer spheres that soak up the drug and release it slowly inside the tumor; and Lipiodol, an oily iodinated contrast agent commonly mixed into the embolic mixture. Each substance was measured first in a clean in-vitro setup, then embedded in pieces of porcine liver to simulate the messy chemical environment of real tissue.

The results were strikingly clear for doxorubicin. The drug’s most prominent spectroscopic signal, produced jointly by a methoxy group and a cycloalkyl group on its molecular structure, appeared at 3.46 plus or minus 0.04 parts per million in solution and at 3.54 plus or minus 0.02 parts per million inside liver tissue, close to the theoretically calculated value of 3.77 parts per million. Crucially, this peak sits in a region of the spectrum that is largely free of signals from endogenous liver metabolites, meaning the drug’s fingerprint stands out against the biological background. When the researchers measured doxorubicin-loaded Embozene beads inside liver tissue, the drug signal remained clearly detectable, and the weak signals from the polymer beads themselves did not interfere with the measurement. In other words, the carrier vanished spectroscopically while the payload remained visible.

Lipiodol told a different story. The oily agent generated enormous signals, ranging from about 0.69 to 2.14 parts per million ex vivo, that dwarfed everything else in the spectrum, including the native lipid peaks of the liver itself. This overwhelming intensity completely swamped the underlying tissue signals, which cuts both ways. On one hand, it means Lipiodol is trivially easy to detect, and its distribution could in principle be mapped spectroscopically. On the other hand, any drug hidden beneath the Lipiodol signal becomes nearly impossible to measure without sophisticated spectral-fitting tools such as LCModel, which are currently designed for metabolites rather than drugs. The authors note that computed tomography already offers validated methods for quantifying Lipiodol deposition after TACE, so a spectroscopic alternative for that specific agent may be unnecessary.

Why does any of this matter? The distribution and duration of intratumoral drug presence after TACE almost certainly varies from patient to patient, and it is reasonable to assume that this variation influences treatment response. Yet no technique in clinical use today can assess drug presence or its spatial and temporal distribution inside the tumor. Researchers have relied on ex-vivo instrumental microanalysis of resected tissue, which captures a static snapshot but misses the actual metabolic processes unfolding at the treatment site. If spectroscopy could be repeated over time in the same patient, it would generate a local drug profile, revealing how long doxorubicin persists in the tumor and whether it spreads uniformly or pools unevenly. That information could support individually adapted TACE protocols, with treatment intervals and drug doses tailored to what the spectrum actually shows rather than what population averages suggest.

The study also addressed a subtle but important pharmacological question: metabolization. Doxorubicin is broken down in the body into several metabolites, most notably doxorubicinol, in which a carbonyl oxygen is hydroxylated, along with aglycones such as doxorubicinone and 7-deoxydoxorubicinone. These transformations have been extensively characterized with techniques like high-performance liquid chromatography and liquid chromatography with tandem mass spectrometry. The encouraging news for spectroscopy is that the signaling methoxy group remains unchanged in all known metabolites, so the measured spectrum should not shift as the drug is metabolized. The researchers also observed that the clinical doxorubicin preparation contained lactose monohydrate as a bulking agent, whose theoretical signal range overlaps the drug’s main peak, potentially amplifying the signal. That quirk hints the method might even extend to other powdered parenteral formulations that use similar excipients.

The authors are candid about the limitations of their setup. Signal strengths varied between measurements, likely due to temperature changes affecting molecular mobility and relaxation times, and to pH-dependent proton exchange in different chemical environments. In-vitro measurements benefit from clean, homogeneous conditions that produce sharp, well-defined peaks, while ex-vivo tissue introduces biological background noise from lipids, proteins, and endogenous metabolites, along with magnetic field inhomogeneities that broaden and distort signals. The 7 Tesla preclinical scanner, though powerful, is still weaker than dedicated nuclear magnetic resonance instruments, which partly explains small deviations between measured and calculated chemical shifts. And the leap from porcine liver in a dish to a living human patient is substantial: in vivo spectroscopy must contend with motion, breathing, and the constraints of clinical field strengths.

Still, the proof of concept lands at a moment of genuine momentum for interventional oncology. TACE is a mainstay therapy for hepatocellular carcinoma, cholangiocellular carcinoma, and certain liver metastases, tumors that are fed predominantly by arterial blood and are therefore ideal targets for transarterial delivery. The regional advantage of intra-arterial chemotherapy, amplified by embolization-induced slowing of blood flow, is well established pharmacologically, but it has never been observable at the level of the individual tumor in real time. If 1H-MRS can be validated in animal models and then in patients, it could become the first bedside tool for confirming that a chemotherapy dose actually landed where it was intended and for tracking how long it lingers. The authors caution that the quality of evaluation will depend on dedicated software tools that still need detailed analysis. But the core message is simple and potentially transformative: the drug’s voice, long drowned out by the noise of tissue, can now be heard, and listening to it may one day make liver cancer therapy a genuinely personalized procedure.

Subject of Research: Proton magnetic resonance spectroscopy for monitoring chemotherapeutic drug delivery after transarterial chemoembolization of liver tumors

Article Title: Feasibility of proton magnetic resonance spectroscopy for the assessment of chemotherapeutic drug delivery after TACE: a proof of concept

Article References: Godzinski, A., Jedelská, J., König, A. M., & Mahnken, A. H. (2025). Feasibility of proton magnetic resonance spectroscopy for the assessment of chemotherapeutic drug delivery after TACE: a proof of concept. CVIR Oncology, 1(1), Article 10. https://doi.org/10.1007/s44343-025-00010-6

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00010-6

Keywords: transarterial chemoembolization, proton magnetic resonance spectroscopy, doxorubicin, liver cancer, drug delivery, drug-eluting beads, Lipiodol, interventional radiology, hepatocellular carcinoma, therapy monitoring, MRI, chemotherapy

The research team, led by Siobhan Lee and Christian Abel of the Department of Medical Imaging with Elliot Lee of the University of New England, took advantage of an unplanned natural experiment. In early November 2021, the locally available formulation of doxorubicin, the anthracycline antibiotic most commonly used in conventional TACE, changed from a dilute 2 mg/mL solution to a concentrated 25 mg/mL preparation. Before the switch, patients received the drug diluted in 25 mL of total emulsion volume; afterwards, the same drug arrived in just 2 mL. Because the change reflected pharmacy supply rather than a deliberate therapeutic strategy, the researchers could compare the two eras without the pressure of a formal trial, analysing 57 consecutive patients who underwent 106 cTACE procedures between September 2019 and February 2024.

The results were strikingly flat. Median overall survival was 788 days, or 25.6 months, in the low-concentration group, compared with 710 days, or 23.3 months, in the high-concentration group, a difference that fell well short of statistical significance with a log-rank p-value of 0.757. Tumour response, assessed with the modified RECIST and EASL criteria at three and six months, showed no meaningful divergence between the groups. Disease-free survival at one, two, and three years was similarly indistinguishable, although the one-year figure, 14.5 percent versus 29.4 percent favouring the high-concentration cohort, approached significance at p = 0.052, a trend the authors flag as worth watching in longer follow-up.

Safety data were equally reassuring for the concentrated formulation. Post-embolization syndrome, the constellation of fever, abdominal pain, and nausea that follows embolization in some patients, occurred in 7.3 percent of the low-concentration group and 5.9 percent of the high-concentration group, a non-significant difference. Other complications were actually numerically less frequent in the concentrated era, at 12.7 percent versus 5.9 percent, and mean hospital admission was essentially identical at 1.35 versus 1.27 days. Interestingly, patients who did develop post-embolization syndrome tended to have larger baseline tumours, with a mean maximal dimension of 52.7 mm versus 35.2 mm, and more often had multifocal disease, echoing prior literature that identifies tumour size as a major predictor of the syndrome.

What did predict survival, powerfully, was disease stage. In Cox proportional hazards regression adjusted for baseline characteristics, patients in Barcelona Clinic Liver Cancer stage B faced a 5.51-fold higher hazard of death compared with stage A, while stage C patients faced an 8.83-fold higher hazard. Mean survival fell from 1543 days in stage A to 817 days in stage B and just 440 days in stage C, a gradient so steep it dominated every other variable. Neither Child-Pugh liver function scores, ECOG performance status, tumour size, nor any treatment factor independently predicted survival once stage was accounted for.

The null result lands in the middle of a long-running and increasingly uncomfortable debate about whether chemotherapy contributes anything at all to transarterial embolization in liver cancer. A foundational 2003 systematic review by Llovet and Bruix found that chemoembolization improved survival over control arms, helping cement cTACE as standard therapy. But a 2011 Cochrane review found insufficient evidence that adding chemotherapy to embolization improved survival, noting low methodological quality and significant risk of bias across the randomised trials. More recently, two separate systematic reviews and meta-analyses of randomised controlled trials directly comparing TACE with bland transarterial embolization, which uses no chemotherapy at all, found no significant difference in overall survival, progression-free survival, or objective response rate. One of those analyses, by Wang and colleagues, went as far as recommending bland embolization on cost grounds, given similar or reduced adverse event rates.

The new study’s findings are, in that light, potentially supportive of a limited therapeutic role for chemotherapy agents in HCC embolization. If a more than twelvefold increase in doxorubicin concentration produces no measurable difference in survival, response, or toxicity, it becomes harder to argue that the drug itself is the engine of the treatment’s benefit. The authors note that the higher-concentration group actually received a higher total doxorubicin dose, a higher Lipiodol-to-doxorubicin ratio of 3.3 versus 1.3, and a smaller total emulsion volume, all differences significant at p < 0.001, yet outcomes did not budge. Lipiodol itself is not merely a carrier; it acts as an embolic agent, inducing tumour ischemia, and prior work has shown that homogeneous Lipiodol retention on post-treatment imaging correlates with better overall and progression-free survival, while higher Lipiodol doses have been linked to more complete tumour necrosis and more stable emulsions in laboratory studies.

The study also sits within the parallel debate over drug-eluting bead TACE, or DEB-TACE, which loads doxorubicin onto calibrated microspheres to standardise delivery and overcome the operator-dependent, freshly mixed emulsion that defines conventional TACE. Meta-analyses comparing the two approaches have produced a patchwork of findings: some report improved response rates with beads, one 2025 review found a small but significant survival advantage of roughly 3.5 months, and others find no difference at all, often with substantial heterogeneity and publication bias. The 2025 European Association for the Study of the Liver guidelines sidestep the controversy by recommending that cTACE and DEB-TACE be considered equivalent, and that bland TAE be considered an acceptable alternative to TACE altogether. Cost analyses suggest drug-eluting beads carry higher upfront expense but may offset this through shorter stays and less post-procedural pain, with one estimate of 2.4 versus 2.0 quality-adjusted life years favouring the beads.

Beyond the headline null result, the study quietly documents an evolution in clinical practice. The later, high-concentration cohort contained significantly more patients with advanced BCLC stage C disease, higher Child-Pugh scores suggesting more severe cirrhosis, and higher ECOG performance status scores, indicating that the centre was progressively offering cTACE to sicker, more comorbid patients. The authors suggest this reflects a deliberate broadening of the treatment population, but it introduces a real risk of selection bias: the modest numerical survival edge in the early group could simply reflect its healthier starting point. The early group also had significantly larger baseline tumours, with a mean maximum dimension of 43 mm versus 31 mm, which correlated with a lower one-year disease-free survival that approached significance.

The authors are candid about the limitations inherent in the retrospective, single-centre design. Documentation of treatment details improved markedly over the study period, and inadequate records accounted for over half of the 35 excluded patients, a factor that may actually improve future research. Time to tumour progression was not calculated because retrospective imaging data were too variable, prompting the authors to use disease-free survival as an umbrella measure instead. The sample size, particularly at later endpoints where only six patients in the high-concentration group reached three years, limits statistical power, and the entanglement of the doxorubicin formulation change with shifts in Lipiodol ratio and emulsion volume cannot be fully disentangled. Still, the core message is difficult to ignore: within the doses used here, where even the high-concentration protocol never exceeded 50 mg of doxorubicin, the concentration of chemotherapy delivered during cTACE appears to matter little for how long patients live, how well their tumours respond, or how they feel afterwards. As the field awaits larger, prospective, multicentre trials, the study adds weight to a provocative possibility that the embolic machinery of TACE, not its chemical cargo, may be doing the heavy lifting.

Subject of Research: Doxorubicin concentration in conventional transarterial chemoembolization for hepatocellular carcinoma

Article Title: High-concentration doxorubicin in cTACE: a retrospective cohort study of efficacy and safety

Article References: Lee, S., Lee, E., & Abel, C. (2025). High-concentration doxorubicin in cTACE: a retrospective cohort study of efficacy and safety. CVIR Oncology, 1(1), Article 19. https://doi.org/10.1007/s44343-025-00022-2

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00022-2

Keywords: hepatocellular carcinoma, transarterial chemoembolization, doxorubicin, Lipiodol, overall survival, post-embolization syndrome, BCLC stage, drug-eluting beads, liver cancer, interventional radiology, chemotherapy, retrospective cohort study

Hepatocellular carcinoma is the most common primary liver malignancy, accounting for 85 to 90 percent of cancers that originate in liver cells, and it ranks as the third leading cause of cancer-related death worldwide. For patients with intermediate-stage disease and preserved liver function, transarterial chemoembolization, or TACE, is a cornerstone of care under the Barcelona Clinic Liver Cancer staging system. The procedure exploits a biological quirk: liver tumors draw their blood supply almost exclusively from the hepatic arteries, while healthy liver tissue depends on the portal vein. By threading a catheter into the arteries feeding the tumor and delivering a mixture of chemotherapy and an oily contrast agent called lipiodol, followed by embolization with gel foam slurry, interventional radiologists can concentrate a cytotoxic assault on the tumor while starving it of blood.

Yet the very act of delivering that assault exposes the hepatic vasculature to a barrage of insults. Catheters and guidewires scrape the vessel walls. Lipiodol and antimitotic drugs such as epirubicin exert corrosive and chemical effects on the delicate endothelial lining. Temporary embolization produces ischemic stress, and patients with chronic liver disease already harbor dysfunctional endothelium that may be poorly equipped to recover. Despite decades of TACE practice, the literature on what actually happens to the native hepatic arteries after treatment has remained surprisingly thin, prompting the research team to investigate systematically.

The researchers, led by interventional radiologists at the Sree Chitra Tirunal Institute for Medical Sciences and Technology in Thiruvananthapuram, Kerala, combed hospital records for all adult patients with chronic liver disease who underwent more than one session of TACE between January 2018 and June 2023. Of 394 patients treated during that window, 69 had undergone repeat sessions, and 58 had angiographic images of sufficient quality for analysis. The team deliberately excluded patients who had received other locoregional therapies, such as radiofrequency ablation, between TACE sessions, to keep the vascular picture as clean as possible.

The analytical framework was elegantly simple. The hepatic vasculature was divided into three anatomical zones: the proximal zone comprising the common hepatic artery and hepatic artery proper, the intermediate zone covering lobar and segmental branches, and the distal zone encompassing the subsegmental branches that represent the liver’s microvascular frontier. Injury was graded on a four-point ordinal scale, ranging from Grade 0 for a normal appearance or mild irregularity, through Grade 1 for mild stenosis of about 50 percent, to Grade 2 for severe stenosis or complete occlusion, and Grade 3 for the presence of pseudoaneurysms or dysplastic arterial changes. Grades 0 and 1 were classified as low-grade injury, while Grades 2 and 3 counted as high-grade. Two radiologists with ten and five years of gastrointestinal imaging experience independently reviewed paired angiograms obtained at least six weeks apart, blinded to clinical details.

The results painted a strikingly zonal picture. In the proximal vessels, 98.3 percent of patients showed Grade 0 injury and the remainder Grade 1, with no high-grade damage at all, and statistical testing confirmed no significant change before and after the first TACE session. The intermediate zone told a different story: 84.5 percent of patients had Grade 0 injury, but 13.8 percent showed Grade 1 and 1.7 percent showed Grade 2, a distribution that shifted significantly after treatment. The distal subsegmental vasculature fared worst of all, with 53.4 percent of patients at Grade 0, 31 percent at Grade 1, 13.8 percent at Grade 2, and 1.7 percent at Grade 3, meaning roughly 12 to 15.5 percent of patients developed high-grade injury to the liver’s smallest arteries. The Mann-Whitney U-test yielded p-values of 0.002 for the intermediate zone and 0.001 for the distal zone, while the proximal zone showed no significant difference. Interobserver agreement was strong, with a correlation coefficient of 0.913.

To understand why some patients’ microvasculature fared worse than others, the team turned to multinomial logistic regression, feeding in demographic, biochemical, clinical and procedural variables. Three factors emerged as independent predictors of high-grade distal arterial injury: the Child-Pugh score, a measure of liver functional reserve; the presence of diabetes; and the delta time, the interval in weeks between successive TACE sessions. Each carried a statistically significant association, with p-values of 0.031, 0.045 and 0.004 respectively. Notably, no variable predicted high-grade injury in the lobar and segmental vessels, reinforcing the impression that the microvasculature is uniquely vulnerable.

The biology behind these predictors is plausible. Diabetes is well known to impair endothelial function and blunt vascular healing, and prior work has shown that adequate glycemic control in TACE patients is associated with improved progression-free survival. Deteriorating liver function, captured by the Child-Pugh score, is likewise linked to poor endothelial resilience and impaired microvascular recovery. The delta time finding may be the most immediately actionable: shorter intervals between embolization sessions give the injured native vasculature less time to recover, so repetitive injury at close intervals compounds itself. This inverse relationship between retreatment interval and vascular damage could inform scheduling decisions, suggesting that clinicians may want to prioritize vascular recovery when planning repeat interventions rather than compressing the timeline.

The clinical stakes are considerable. Patency of segmental and subsegmental arteries is paramount for delivering a second round of chemoembolization to residual or recurrent tumor, so distal vascular injury could compromise both the feasibility and efficacy of retreatment, and may even encourage the tumor to recruit alternative extrahepatic blood supplies. Conversely, the apparent invulnerability of the proximal hepatic arteries is reassuring for the substantial subset of patients who undergo TACE as a bridge to liver transplantation, since damage to the main hepatic artery could complicate the transplant operation itself. Prior multicenter analyses of more than 800 patients who received TACE before transplantation found no increased need for intraoperative hepatic artery interventions, a conclusion this study’s proximal findings echo. The authors also raise the possibility that transarterial radioembolization, generally considered gentler on the vasculature, may be preferable for patients anticipated to need multiple locoregional treatments.

The study has limitations that temper but do not erase its message. It assessed only the changes following the first TACE session to maintain homogeneity, so cumulative injury from multiple sessions remains unmeasured. It was a single-center analysis with a modest sample, and all patients received conventional TACE rather than drug-eluting bead or balloon-occlusion variants, so the findings may not generalize to those techniques. Still, the authors report that no previous study has systematically documented the incidence of hepatic arterial injury after chemoembolization, making this a genuine first. Larger, prospective, multicenter trials will be needed to confirm the predictors and to determine whether protecting the liver’s smallest arteries can translate into better outcomes for patients facing repeated rounds of therapy against one of the world’s deadliest cancers.

Subject of Research: Vascular injury to hepatic arteries following transarterial chemoembolization for hepatocellular carcinoma

Article Title: Angio-architectural changes in hepatic arteries following conventional transarterial chemoembolization for hepatocellular carcinoma and the factors influencing them: a retrospective observational study

Article References: Arunachalam, V. S., Sharma, S., Ayyappan, A., Alex, A., & Valakkada, J. (2025). Angio-architectural changes in hepatic arteries following conventional transarterial chemoembolization for hepatocellular carcinoma and the factors influencing them: a retrospective observational study. CVIR Oncology, 1(1), Article 28. https://doi.org/10.1007/s44343-025-00028-w

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00028-w

Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic artery, vascular injury, interventional radiology, angiography, microvasculature, Child-Pugh score, diabetes, lipiodol, liver cancer, endothelial dysfunction